Therapy Areas: Devices
WAT Medical to market EmeTerm and HeadaTerm in Australia following TGA Australia's approval
3 June 2019 -

Medical products company WAT Medical stated on Monday that its migraine treatment product HeadaTerm has received official clearance from TGA Australia.

The company said it now plans to supply its HeadaTerm device for individual customers worldwide through its Australian partner Homemed, part of the BMedical Group Pty Ltd, a web-based store that offers a complete selection of products to aid in the treatment of sleep apnoea, snoring and insomnia across Australia and New Zealand.

According to the company, HeadaTerm uses neuromodulation by sending precise electrical pulses to the target area in the brain responsible for endorphin release. It relieves migraine within a few minutes after initial headache and can be an effective preventive measure by reducing the frequency and intensity of migraine attacks. It is a reasonably priced disposable device. Its compact and lightweight design makes it very portable, providing consumers with fast and convenient migraine treatment.

In conjunction, HeadaTerm has received marketing approvals from the FDA (US), HC (Canada) as well as CE (EU).

Additionally, the company's anti-nausea device, EmeTerm, based on neuromodulation technology, was already approved and clinically proven by TGA Australia in 2018. The device delivers patented current stimulation through P6 accupoint on the underside of wrist. The electrical impulses are delivered to targets in brain and accurately block vomiting signals from brain to stomach. It is currently used by consumers in 20 countries around the world, including Europe, the US, Australia and Canada.